Anti-hyperglycemic and Anti-lipidemic activities of Diabac (a polyherbal formulation) in Streptozotocin-nicotinamide induced type 2 diabetic rats

Richa Agrawal, Rajesh Maheshwari, Ramachandran Balaraman and Avinash Seth

Department of Pharmacy, Sumandeep Vidyapeeth, Piparia, Vadodara, Gujarat, India.

ABSTRACT

Aim: The objective of the work was to investigate the antidiabetic activity of Diabac (a polyherbal formulation) in streptozotocin-nicotinamide induced type 2 diabetic rats. Methods: Oral glucose tolerance test (OGTT) was performed to evaluate effect of Diabac on elevated glucose level. The type 2 diabetes was induced by overnight fasted rats by a single intraperitoneal (i.p.) injection of 65 mg/kg streptozotocin, 15 min. after the i.p. administration of 110 mg/kg nicotinamide. The diabetic rats were treated with Diabac (250, 500 and 1000 mg/kg, p.o.) or glibenclamide (5 mg/kg, p.o) for four weeks. Various parameters were studied such as fasting blood sugar level, serum insulin levels, glycated hemoglobin (HbA\textsubscript{1C}), serum lipid levels, serum creatinine, urea, and uric acid, whereas there was a decrease in serum insulin, liver glycogen and HDL-C levels as compared to normal control rats. The administration of Diabac or glibenclamide significantly decreased the levels of glycated hemoglobin, serum lipids, serum creatinine, urea and uric acid, whereas there was an increase in the levels of liver glycogen and HDL-C as compared to diabetic control rats. However, the treatment with Diabac did not show any significant change in serum insulin levels as compared to diabetic control rats. Conclusion: These results of present study concluded that Diabac has anti-diabetic and anti-lipidemic activities which are responsible for its use in traditional medicine.

Key words: Diabac, Glycated hemoglobin, Liver glycogen, Serum lipids, Streptozotocin.

SUMMARY

- Administration of Diabac (250, 500 and 5000 mg/kg), a polyherbal formulation to the STZ-nicotinamide induced diabetes resulted in a decrease the levels of fasting blood sugar, glycated hemoglobin, TG, TC, LDL-C, serum creatinine, urea and uric acid, whereas there was an increase in the levels of liver glycogen and HDL-C as compared to diabetic control rats.

INTRODUCTION

Diabetes mellitus is a metabolic disorder characterized by hyperglycemia resulting from the defects in insulin secretion, insulin resistance or both. It is considered to be one of the five foremost causes of death in the world. There are reports that incidence of diabetes mellitus was 2.8% in 2000 and is expected to increase to 4.4% in 2030. For a long time, diabetes mellitus has been treated with a number of medicinal plants or their extracts based on folklore medicine. The oral hypoglycemic agents (sulfonylurea, biguanide, thiazolidinedione, α-glycosidase inhibitor and DPP-IV inhibitor) can produce several undesirable side effects and in addition, they are not suitable for use in pregnancy. Thus, the management of diabetes without any side effects is still a challenge. Therefore, the search for more effective and safer hypoglycemic agents has continued to be an important area of active research. Since, the oral hypoglycemic agents cause several side effects it has become a need to search for more effective and safer hypoglycemic agents. Since, there is no scientific evidence of this herbal formulation in the world.

MATERIALS AND METHODS

Drugs and chemicals

Diabac (Bacfo Pharmaceuticals India Limited, Noida), Streptozotocin, nicotinamide (Himedia, Mumbai, India) and Glibenclamide (USV Limited) are the main drugs used in present study. All biochemical kits were purchased from Span diagnostics Ltd, Surat, India and other chemicals and reagents used in the study were of analytical grade.

Experimental animals

Albino Wistar rats (200-250 g) of either sex were obtained from Zy dus Research Centre, Ahmedabad. All animals were maintained under standardized condition (12-h light/dark cycle, 24 ± 2°C & humidity 35-60 %) and they were provided with standard pellet diet and water ad libitum. The rats were left for 48 h for adaptation prior to the beginning of the experiment. The study was approved by Institutional Animal Ethics Committee (IAEC) and carried out in accordance with CPCSEA (Committee for the Purpose of Control and Supervision of Experiment on Animal) guidelines.
Acute toxicity study
At the basis OECD guideline no. 423, the acute oral toxicity was carried out in albino Wistar rats of either sex weighing 200-250 g. Diabac was given at the dose of 100, 200, 500, 1000, 2000 and 5000 mg/kg, p.o. for 3 animals and the signs and symptoms were observed after 0, 30, 60, 120, 180, 240 min and then once a day for next 14 days.

Oral glucose tolerance test (OGTT)
Oral glucose tolerance test was performed in overnight (12h) fasted normal rats. Rats were divided into five groups of six each. Groups 1 received drinking water. Groups 2 received glibenclamide (5 mg/kg, p.o.), group 3-5 received Diabac (250, 500 and 1000 mg/kg, p.o.). Glucose (2 g/kg, p.o.) was fed 30 min prior to the administration of above-mentioned treatments. Blood glucose levels were measured by collecting the blood samples from the tail vein and they were collected at 0, 30, 60, 90 and 120 minutes after the glucose loading and blood glucose levels were measured.

Induction of type 2 diabetes
Sreptozotocin (65 mg/kg, i.p.) and nicotinamide (110 mg/kg, i.p.) were administered to overnight fasting albino Wistar rats (200-250 g) to induce Type 2 diabetes. Nicotinamide (dissolved in normal saline) was given first and 15 minutes later streptozotocin (dissolved in citrate buffer, pH 4.5) was administered. Hyperglycemia was confirmed by elevated blood glucose levels at 72 h and then on day 7 after injection and only animals with fasting blood glucose level greater than 200 mg/dl were selected for antidiabetic study.

Experimental design
The rats were divided into six groups each consisting of six animals.

Group I: Normal control rats (distilled water 1 ml/kg, p.o.).
Group II: Diabetic control rats.
Group III: Diabetic rats treated with glibenclamide (5 mg/kg, p.o.).
Group IV: Diabetic rats treated with Diabac (250 mg/kg, p.o.).
Group V: Diabetic rats treated with Diabac (500 mg/kg, p.o.).
Group VI: Diabetic rats treated with Diabac (1000 mg/kg, p.o.).
All the aforementioned treatments were started one week (7 days) after induction of diabetes and treatments continued for 28 days.

The fasting blood sugar levels were measured on 1, 7, 14, 21 and 28 days periodically. Urine volume and urine glucose contents were estimated. At the end of the experiments, blood samples were collected from the retro orbital plexus of rats under light ether anesthesia, using glass capillaries and stored in with or without disodium ethylene diamine tetra-acetate for estimation of biochemical parameters. After, allowing the blood to clot for serum separation for 15 minutes, it was centrifuged at 5000 rpm for 20 minutes for separation of serum. Then the serum was stored at -20°C until further estimation.

Blood glucose, glycated hemoglobin (HbA1c), hemoglobin (Hb) were estimated using whole blood. The total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL-C), high density lipoprotein (HDL), serum creatinine, urea and uric acid were estimated from serum using standard diagnostic kit. The serum insulin was determined by radioimmunoassay method. Glycogen level in liver was determined as according to the method of Roe et al.

Histopathology
After sacrifice, pancreas tissues of each group were rapidly dissected out and washed immediately with saline and fixed in 10% phosphate buffered formalin. Paraffin-embedded specimens were cut into 5 μm-thick sections and stained with hematoxylin and eosin (H&E). The sections were examined under the light microscope (Olympus BX10, Tokyo, Japan) for the presence of histopathological changes and photomicrographs (Olympus DP12 camera, Japan) were taken. The observer performing histopathological evaluation was blinded to the animal treatment groups.

Statistical analysis
All the data are expressed as mean ± SEM (n=6). The statistical significance between more than two groups was tested using one-way ANOVA followed by the Bonferroni multiple comparisons post test using a computer-based fitting program (Prism, GraphPad version 5, GraphPad software, Inc). The significance level was set at P<0.05 for all tests.

RESULTS

Acute oral toxicity
The administration of Diabac up to a dosage 5000 mg/kg did not show any sign of toxicity and no mortality for 14 days. Therefore, the pharmacological studies were carried out using 1/20th (250 mg/kg), 1/10th (500 mg/kg) and 1/5th (1000 mg/kg) dose levels of Diabac.

Effect of Diabac on oral glucose tolerance test (OGTT)
Glucose challenge to normal rats increased blood glucose levels with maximum at 60 min and slight reduction in blood glucose was observed at 90 min onwards. The treatment with Diabac or glibenclamide improved glucose tolerance significantly at 60 min to 120 min compared to normal control animals (Table 2).

Effect of Diabac on fasting blood glucose levels
The effect of Diabac on fasting blood glucose level of diabetic rats is shown in Table 3. Diabetic rats showed a significant increase in the fasting blood glucose levels as compared to normal control rats. At day 14 onwards, treatment with Diabac (250, 500 and 1000 mg/kg) showed a significant dose dependent decrease in blood glucose levels as compared to normal control rats.
Effect of Diabac on body weight, urine volume and urine glucose

Diabetic rats showed a significant decrease (P<0.001) in body weight compared to normal control rats. However, treatment with Diabac (500 and 1000 mg/kg, p.o.) or glibenclamide did not show any significant reduction in body weight as compared to diabetic control, while Diabac (250 mg/kg) treated rats showed a significant reduction in body weight. Administration of Diabac or glibenclamide to diabetic rats showed a significant (P<0.001) reduction in urine volume as compared to diabetic control rats. An effect of Diabac or glibenclamide on urine glucose is shown in Table 4.

Effect of Diabac on Hemoglobin, Glycated hemoglobin, serum insulin and liver glycogen levels

Diabetic rats showed a significant (P<0.001) elevation in the level of glycated hemoglobin (HbA1c) and reduction in the level of hemoglobin (Hb), serum insulin as compared to normal control rats. The treatment with Diabac (250, 500 and 1000 mg/kg, p.o.) or glibenclamide (5 mg/kg, p.o.) showed a significant (P<0.001) reduction in levels of glycated hemoglobin and an increase in the level of Hb at dose dependant manner. In contrast, treatment with Diabac did not show any significant alteration in serum insulin levels as compared to diabetic untreated rats. Liver glycogen levels of diabetic rats were significantly decreased as compared to diabetic control rats. An effect of Diabac on liver glycogen levels is shown in Table 4.

Effect of Diabac on serum lipid levels

Diabetic rats showed a significant (P<0.001) increase in the level of TG, TC and LDL-C and a reduction in level of HDL-C as compared to normal control rats. Treatment with Diabac (500 and 1000 mg/kg) showed a significant reduction in level of TG (P<0.001), TC (P<0.001), LDL-C (P<0.001) and an increase in HDL-C (P<0.01; P<0.001) levels in diabetic rats when compared to diabetic control rats. Moreover, treatment with Diabac (250 mg/kg) showed a significant decrease in levels of TG (P<0.001), TC (P<0.05), LDL-C (P<0.01) and did not show any sig-

Table 2: Effect of Diabac on oral glucose tolerance test in non-diabetic rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>Treatment</th>
<th>Blood glucose (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0 min</td>
</tr>
<tr>
<td>1</td>
<td>Normal control</td>
<td>102.3 ± 3.25</td>
</tr>
<tr>
<td>2</td>
<td>Glibenclamide (5 mg/kg)</td>
<td>95.83 ± 2.18</td>
</tr>
<tr>
<td>3</td>
<td>Diabac (250 mg/kg)</td>
<td>102.3 ± 4.21</td>
</tr>
<tr>
<td>4</td>
<td>Diabac (500 mg/kg)</td>
<td>98.17 ± 3.71</td>
</tr>
<tr>
<td>5</td>
<td>Diabac (1000 mg/kg)</td>
<td>96.50 ± 2.66</td>
</tr>
</tbody>
</table>

Values are expressed in mean ± S.E.M (n=6), where “*P<0.05, “**P<0.01, “***P<0.001 as compared to normal control.

Table 3: Effect of Diabac on fasting blood glucose levels in STZ-nicotinamide induced type II diabetes

<table>
<thead>
<tr>
<th>Groups</th>
<th>Treatment</th>
<th>Fasting Blood glucose (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Day 1</td>
</tr>
<tr>
<td>1</td>
<td>Normal control</td>
<td>73.67 ± 1.706</td>
</tr>
<tr>
<td>2</td>
<td>Diabetic control</td>
<td>243.7 ± 12.73</td>
</tr>
<tr>
<td>3</td>
<td>Glibenclamide (5 mg/kg)</td>
<td>297.7 ± 26.70</td>
</tr>
<tr>
<td>4</td>
<td>Diabac (250 mg/kg)</td>
<td>322.5 ± 33.77</td>
</tr>
<tr>
<td>5</td>
<td>Diabac (500 mg/kg)</td>
<td>293.0 ± 19.90</td>
</tr>
<tr>
<td>6</td>
<td>Diabac (1000 mg/kg)</td>
<td>288.8 ± 15.75</td>
</tr>
</tbody>
</table>

Values are expressed in Mean ± S.E.M (n=6), where “*P<0.05, “**P<0.01, “***P<0.001 as compared to normal control.

Table 4: Effect of Diabac on body weight, urine volume and urine glucose in STZ-nicotinamide induced type II diabetes

<table>
<thead>
<tr>
<th>Groups</th>
<th>Treatment</th>
<th>Initial body weight (g)</th>
<th>Final body weight (g)</th>
<th>Urine Volume (ml)</th>
<th>Urine glucose</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Normal control</td>
<td>275.0 ± 10.25</td>
<td>266.7 ± 11.45</td>
<td>20.83 ± 1.24</td>
<td>Nil</td>
</tr>
<tr>
<td>2</td>
<td>Diabetic control</td>
<td>216.7 ± 10.54</td>
<td>173.3 ± 8.02</td>
<td>54.33 ± 2.81</td>
<td>+++</td>
</tr>
<tr>
<td>3</td>
<td>Glibenclamide (5 mg/kg)</td>
<td>213.3 ± 6.14</td>
<td>203.3 ± 7.14</td>
<td>25.00 ± 1.34</td>
<td>Nil</td>
</tr>
<tr>
<td>4</td>
<td>Diabac (250 mg/kg)</td>
<td>211.7 ± 8.33</td>
<td>185.0 ± 9.91</td>
<td>43.17 ± 1.27</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>Diabac (500 mg/kg)</td>
<td>220.0 ± 10.65</td>
<td>204.2 ± 7.79</td>
<td>35.00 ± 0.93</td>
<td>Nil</td>
</tr>
<tr>
<td>6</td>
<td>Diabac (1000 mg/kg)</td>
<td>216.7 ± 8.43</td>
<td>209.2 ± 8.40</td>
<td>28.33 ± 1.02</td>
<td>Nil</td>
</tr>
</tbody>
</table>

Values are expressed as Mean + S.E.M (n=6), Where, “*P<0.01 as compared to normal control; “**P<0.01, “***P<0.001 as compared to diabetic control.

(+): Trace elements of sugar and (++): more than 2% of sugar.
significant changes in HDL-C level as compared to diabetic untreated rats (Table 6).

**Effect of Diabac on serum creatinine, urea and uric acid**

There was a significant (P<0.001) increase in the level of serum creatinine, urea and uric acid in diabetic control rats as compared to normal control rats. The administration of Diabac (500 and 1000 mg/kg) showed a significant decrease in the level of serum creatinine (P<0.001), urea (P<0.001) and uric acid (P<0.05; P<0.001) as compared to diabetic control rats. In addition, treatment with Diabac (250 mg/kg) showed a significant decrease in levels of serum creatinine (P<0.05), urea (P<0.001) and did not show any significant differences in uric acid level as compared to diabetic untreated rats (Table 7).

**Histopathological study**

In normal control rats, appearance of pancreas was shown normal. Pancreas of diabetic control rats showing reduced islet cells. However, the treatment with Diabac showed a recovery of islet cells to near normal appearance (Figure 1).

**DISCUSSION**

Administration of streptozotocin-nicotinamide caused diabetes, which may be because of destruction of beta cells of the islet of Langerhans of the pancreas. Excessive production and decreased utilization of glucose by the tissue are the fundamental basis of hyperglycemia in diabetes mellitus. When Diabac was administered to glucose loaded overnight fasted normal rats, hypoglycemia was observed after 60 min. The reduction in blood glucose levels was reached at its maximum at 2 h. In current study, administration of Diabac showed a significant reduction in blood glucose levels in streptozotocin-nicotinamide induced hyperglycemia. This effect might be due to diminish hepatic glycogenolysis, gluconeogenesis and increased utilization of glucose by the tissues.

In diabetic control rats, glycated hemoglobin levels were found to be increased as compared to normal control rats due to the persistent hyper-
glycemia. It was previously revealed that elevation in non-enzymatic and autooxidation glycosylation in one of the probable mechanisms concerning the hyperglycemia and the vascular complications.25 Treatment with Diabac showed a significant reduction in the glycated hemoglobin levels. The ability of Diabac to reduce glycated hemoglobin levels in diabetic rats showed it's potentiality to prevent the diabetic associated complication. In diabetes, insulin deficiency leads to decrease in protein synthesis in all tissue and thus the synthesis of hemoglobin is also reduced.26 Administration of Diabac significantly increased hemoglobin levels in diabetic rats. Streptozotocin-nicotinamide induced diabetes is characterized by severe reduction in body weight due to increased muscle destruction or degradation of structural proteins.27 When diabetic rats were treated with Diabac, it showed an improvement in body weight as compared to untreated diabetic rats, which may be due to its protective effect in controlling the muscle wasting i.e. reversal of gluconeogenesis and the improvement in glycemic control.

Coronary heart disease and cerebrovascular disease are more common in diabetes. The atherogenic situation is proceeding at a more rapid rate in diabetic than non-diabetic subjects.28 The elevation in levels of triglycerides, total cholesterol, LDL-C and decreased HDL-C levels were reported in diabetic condition.29 In current study, administration of Diabac significantly decreased elevated levels of triglycerides, total cholesterol, LDL-C and increased level of HDL-C in diabetic rats as compared to diabetic control rats. Lipid lowering effect of Diabac might be helpful in controlling diabetic linked complication.

Protein glycation in diabetes might be accountable for muscle wasting and increased release of purine, major source of uric acid, as well as increased the activity of xanthine oxidase.30,31 Administration Diabac significantly reduced the serum creatinine, urea and uric acid levels in diabetic rats. These findings supports that Diabac improved kidney function in diabetic condition and for that reason, it helps to prevent diabetic related early renal damage.

In earlier study, it has been observed that hepatic glycogen is decreased during diabetes.32 In the study, deficiency of insulin in the diabetic condition may result in the inactivation of glycogen synthase. The significant increase in hepatic glycogen content of Diabac treated diabetic rats may be because of the reactivation of glycogen synthase system. Histopathological studies also supported our results. Diabetic rats showed reduced islet cells, which were restored to normal upon treatment with Diabac. There were no alterations found in normal rats.

CONCLUSION

From this study, it was concluded that Diabac has a significant antidiabetic effect. The Diabac also showed improvement in lipid profile, body weight and renal function in diabetic condition. Therefore it might be helpful in preventing diabetic associated complication. Our present investigation supports the conventional use of Diabac in the management of diabetes.

ACKNOWLEDGEMENT

We are sincerely thankful to Baco Pharmaceuticals India limited, Noida for providing financial support and their sample to carry out the study.

CONFLICT OF INTEREST

We declare that we have no conflict of interest.

REFERENCES


ABOUT AUTHORS

Dr. Rajesh Maheshwari: Presently working as Assistant Professor at Department of Pharmacy, Sumandeep Vidyapeeth, Vadodara. He has 6 years of teaching and 3 years of industrial experience. He has published 11 research papers and also presented several research papers in various conferences. He has guided more than 10 students for M.Pharm dissertation.

Dr. Ramachandran Balaraman: Presently working as professor of Pharmacology at Department of Pharmacy, Sumandeep Vidyapeeth, Vadodara, India & formerly Professor & Head at Pharmacy Department, The M S University of Baroda, India. He has 38 years of teaching experience and has published more than 125 research papers in international and national journals with H-index of 24 and citation of more than 2000. He won several awards like Dr. Ohalla oration award; Dr. Lalita Kameshwaran oration award; Dr. Uvanas prize etc. More than 20 students got Ph. D under his guidance and he got the most prestigious award namely Fellow of Academy of Medical Sciences (FAMS) by the NAMS. He was also vice president of Indian Pharmacological Society for year 2007.